These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 6139800)

  • 81. Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: effects of clonidine.
    Izzo JL; Santarosa RP; Larrabee PS; Smith RJ; Kallay MC
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S225-9. PubMed ID: 2455184
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Sympathetic responsiveness and antihypertensive effect of beta-receptor blockade in essential hypertension.
    Distler A; Keim HJ; Cordes U; Philipp T; Wolff HP
    Am J Med; 1978 Mar; 64(3):446-51. PubMed ID: 25017
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Pharmacology of adrenergic beta receptor blockaders].
    Román O
    Rev Med Chil; 1991 May; 119(5):577-83. PubMed ID: 1688229
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Hypotensive mechanisms of beta blockers.
    Conway J
    Eur Heart J; 1983 Jul; 4 Suppl D():43-51. PubMed ID: 6137382
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Comparative effects on renal function of 4 beta-blockers injected intravenously].
    Pozet N; Hadj Aissa AH; Labeeuw M; Zech P
    J Pharmacol; 1983; 14 Suppl 2():133-41. PubMed ID: 6138463
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity.
    Nilsson OR; Karlberg BE; Ohlsson O; Thulin T; Tolagen K
    Acta Med Scand; 1979; 206(4):303-8. PubMed ID: 506802
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Differences in betablocking drugs in cardiovascular therapy.
    Iisalo E; Heikkilä J
    Ann Clin Res; 1988; 20(5):324-33. PubMed ID: 2905877
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Renin-angiotensin-aldosterone system in the treatment of essential hypertension with a beta-adrenergic blocker: sotalol].
    Psadas C; Sánchez G; Zaldívar HM; Rangel J; Cuéllar A; Serrano PA
    Arch Inst Cardiol Mex; 1977; 47(2):160-70. PubMed ID: 901052
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Hemodynamic long-term effects of a beta-receptor blockader (Pindolol) in primary essential hypertension].
    Klein WW; Brandt D; Fluch N; Goebel R; Holzer H; Pöch G
    Adv Clin Pharmacol; 1976; 11():79-85. PubMed ID: 1032573
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Recognizing and treating two types of long-term vasoconstriction in hypertension.
    Laragh JH; Resnick LM
    Kidney Int Suppl; 1988 Sep; 25():S162-74. PubMed ID: 3054233
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Antihypertensive therapy with a new beta-blocking agent Timolol. Double blind study and comparison with Alprenolol and Pindolol (author's transl)].
    Wessels F; Heinze A; Werth HW
    Med Klin; 1977 Oct; 72(41):1689-95. PubMed ID: 335203
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Considerations on physiopathological approaches to the treatment of hypertension.
    Zanchetti A; Leonetti G; Morganti A; Terzoli L
    Clin Exp Pharmacol Physiol Suppl; 1978; 4():1-9. PubMed ID: 28189
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effects of beta-adrenergic blocking agents on the blood pressure, plasma renin activity and hemodynamics of hypertensive patients.
    Matsunaga M; Hara A; Ogino K; Motohara S; Saito M
    Jpn Heart J; 1977 Jan; 18(1):24-30. PubMed ID: 15142
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Beta-adrenoceptor stimulating and blocking agents in essential hypertension: single and combined therapy with terbutaline and metoprolol.
    Schulte KL; Meyer-Sabellek W; Thiede HM; Röcker L; Gotzen R
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):539-44. PubMed ID: 3323072
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Acute effect of atenolol on hemodynamic, plasma renin activity and plasma aldosterone concentration in the once daily oral administration.
    Sasaki Y; Arakawa K
    Jpn Circ J; 1984 Sep; 48(9):988-93. PubMed ID: 6384568
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Beta adrenergic drugs in arterial hypertension].
    Gysling E
    Union Med Can; 1972 Jul; 101(7):1336-41. PubMed ID: 4402882
    [No Abstract]   [Full Text] [Related]  

  • 97. Haemodynamic effects of intravenous beta-blocking drugs in coronary heart disease.
    Taylor SH; Silke B; Nelson GI
    J Pharmacol; 1983; 14 Suppl 2():157-67. PubMed ID: 6138465
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The effect of beta blockers on total peripheral resistance.
    Man in 't Veld AJ; van den Meiracker A; Schalekamp MA
    J Cardiovasc Pharmacol; 1986; 8 Suppl 4():S49-60. PubMed ID: 2427853
    [TBL] [Abstract][Full Text] [Related]  

  • 99. alpha-Methyldopa and beta-blockers in hypertension--a comparison of their haemodynamic effects.
    Lund-Johansen P
    Clin Exp Pharmacol Physiol Suppl; 1978; 4():23-34. PubMed ID: 28190
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity.
    Hansson L
    Acta Med Scand Suppl; 1973; 550():1-40. PubMed ID: 4201751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.